Inhibitor of 5α-Reductase Dutasteride in the Treatment of Benign Prostatic Hyperplasia: Systematic Review and Meta-Analysis

    May 2021
    Maksym Romaniuk, P. Aksonov
    TLDR Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
    The systematic review and meta-analysis evaluated the efficacy and safety of dutasteride, a 5-alpha-reductase inhibitor, in treating benign prostatic hyperplasia (BPH). The analysis included four studies with 1,879 patients and found that dutasteride significantly reduced the need for prostate surgery and episodes of acute urinary retention compared to finasteride, while maintaining a similar safety profile. No statistically significant differences in safety were observed between dutasteride and finasteride, highlighting dutasteride's superior clinical efficacy in managing BPH symptoms.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 2 years ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

      community Serenoa repens (Saw palmetto)

      in Chat  1 upvotes 3 days ago
      Saw palmetto, a 5-alpha reductase inhibitor, caused unexpected side effects like breast changes and altered semen consistency, which resolved after stopping its use. Concerns about similar side effects with finasteride or dutasteride were expressed, and another user reported low libido and depression from saw palmetto.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Similar Research

    6 / 1000+ results